Lupin has launched Meloxicam Capsules, 5 mg, and 10 mg, having received an approval from the United States Food and Drug Administration (USFDA). Meloxicam Capsules, 5 mg and 10 mg, is the generic equivalent of Vivlodex Capsules, 5 mg and 10 mg, of Zyla Life Sciences US, Inc., and indicated for management of osteoarthritis (OA) pain.
Meloxicam Capsules (RLD: Vivlodex) had an annual sales of approximately $11 million in the U.S. (IQVIA MAT October 2020).
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.
